The purpose of this review is to provide an overview of the current status of lipid-lowering therapy utilization and lipid goal attainment in women. We focus on lipid-lowering therapy in individuals with and without established atherosclerotic cardiovascular disease, as well as familial ...
Elderly patients, particularly those older than 75years, have not been well represented in randomized clinical trials evaluating lipid lowering therapy. The limited available data from clinical trials do support the benefit of statin therapy in the elderly population. Based upon these data, cholesterol...
Several studies have shown that effective lipid-lowering therapy slows the progression of atherosclerotic lesions in the coronary and carotid arteries. Recent clinical trials have confirmed and extended previous work showing that lowering cholesterol reduces the risk of coronary events. A clear reduction ...
Elderly patients, particularly those older than 75 years, have not been well represented in randomized clinical trials evaluating lipid lowering therapy. The limited available data from clinical trials do support the benefit of statin therapy in the elderly population. Based upon these data, ...
In conclusion, statin therapy and lipid lowering in general not only confers primary and secondary cardiovascular protection, but is an emerging and exciting adjunctive therapy in gaining control in exudative diabetic maculopathy, where argon laser therapy has traditionally been the only treatment option....
A Steinmetz - 《Diabetes/metabolism Research & Reviews》 被引量: 114发表: 2010年 Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent Treatment of atherosclerosis has mainly focused on decreasing low-density lipoprotein cholesterol (LDL-C). However, ...
Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. Robinson JG.Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly:opportunities and challenges[J].Drugs Aging,2009,26(11... JG Robinson - 《...
Several patient groups also derive clear benefit from cholesterol-lowering drug therapy to reduce risk. Statins are first-line agents: initiation is recommended for all patients treated for secondary prevention, patients with familial hypercholesterolemia, and essentially all adults aged 40 to 75 ...
Over a 2-year period, only modest intensifications of lipid-lowering therapies were observed (17.1%), with only 1 in 3 patients achieving a low-density lipoprotein cholesterol level less than 70 mg/dL at 2 years. Meaning Further lipid-lowering therapy intensification efforts are needed to ...
select article Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts Review articleOpen access Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tum...